Log in

NASDAQ:RYTMRhythm Pharmaceuticals Stock Price, Forecast & News

$18.94
-0.97 (-4.87 %)
(As of 06/4/2020 04:00 PM ET)
Add
Compare
Today's Range
$18.85
Now: $18.94
$20.04
50-Day Range
$16.82
MA: $19.19
$20.40
52-Week Range
$12.99
Now: $18.94
$25.84
Volume127,991 shs
Average Volume235,209 shs
Market Capitalization$835.10 million
P/E RatioN/A
Dividend YieldN/A
Beta0.94
Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Read More
Rhythm Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.50 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RYTM
CUSIPN/A
Phone857-264-4280

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.40 per share

Profitability

Net Income$-140,730,000.00

Miscellaneous

Employees54
Market Cap$835.10 million
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive RYTM News and Ratings via Email

Sign-up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter.

Rhythm Pharmaceuticals (NASDAQ:RYTM) Frequently Asked Questions

How has Rhythm Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Rhythm Pharmaceuticals' stock was trading at $15.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, RYTM shares have increased by 26.3% and is now trading at $18.94. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Rhythm Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 1 sell rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Rhythm Pharmaceuticals.

When is Rhythm Pharmaceuticals' next earnings date?

Rhythm Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Rhythm Pharmaceuticals.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) released its earnings results on Monday, May, 4th. The company reported ($0.78) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.02. View Rhythm Pharmaceuticals' earnings history.

What price target have analysts set for RYTM?

7 brokers have issued 12-month price objectives for Rhythm Pharmaceuticals' stock. Their forecasts range from $18.00 to $43.00. On average, they anticipate Rhythm Pharmaceuticals' share price to reach $34.29 in the next twelve months. This suggests a possible upside of 81.0% from the stock's current price. View analysts' price targets for Rhythm Pharmaceuticals.

Has Rhythm Pharmaceuticals been receiving favorable news coverage?

Headlines about RYTM stock have been trending negative on Friday, InfoTrie reports. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rhythm Pharmaceuticals earned a daily sentiment score of -2.7 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutRhythm Pharmaceuticals.

Are investors shorting Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals saw a decrease in short interest during the month of May. As of May 15th, there was short interest totaling 1,440,000 shares, a decrease of 16.3% from the April 30th total of 1,720,000 shares. Based on an average daily trading volume, of 246,300 shares, the short-interest ratio is currently 5.8 days. Currently, 4.3% of the shares of the company are short sold. View Rhythm Pharmaceuticals' Current Options Chain.

Who are some of Rhythm Pharmaceuticals' key competitors?

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Who are Rhythm Pharmaceuticals' key executives?

Rhythm Pharmaceuticals' management team includes the following people:
  • Dr. Keith Michael Gottesdiener, Pres, CEO & Director (Age 65)
  • Mr. Hunter C. Smith, CFO & Treasurer (Age 50)
  • Ms. Nithya Desikan, Chief Commercial Officer (Age 40)
  • Mr. Leonardus H.T. van der Ploeg, Chief Scientific Officer (Age 64)
  • Mr. Simon D. Kelner, Chief HR Officer (Age 46)

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Janus Henderson Group PLC (9.80%), Primecap Management Co. CA (8.03%), Wellington Management Group LLP (6.05%), BlackRock Inc. (5.67%), Federated Hermes Inc. (5.14%) and State Street Corp (2.22%). Company insiders that own Rhythm Pharmaceuticals stock include Der Ploeg Leonardus HT Van, Keith Michael Gottesdiener, Nithya Desikan and Todd Foley. View institutional ownership trends for Rhythm Pharmaceuticals.

Which institutional investors are selling Rhythm Pharmaceuticals stock?

RYTM stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Morgan Stanley, JPMorgan Chase & Co., Deutsche Bank AG, Wells Fargo & Company MN, SG Americas Securities LLC, and Virtus ETF Advisers LLC. Company insiders that have sold Rhythm Pharmaceuticals company stock in the last year include Nithya Desikan, and Todd Foley. View insider buying and selling activity for Rhythm Pharmaceuticals.

Which institutional investors are buying Rhythm Pharmaceuticals stock?

RYTM stock was purchased by a variety of institutional investors in the last quarter, including Primecap Management Co. CA, Rock Springs Capital Management LP, Aviva PLC, Federated Hermes Inc., Martingale Asset Management L P, Geode Capital Management LLC, State Street Corp, and Bessemer Group Inc.. View insider buying and selling activity for Rhythm Pharmaceuticals.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $18.94.

How big of a company is Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals has a market capitalization of $835.10 million. The company earns $-140,730,000.00 in net income (profit) each year or ($3.86) on an earnings per share basis. Rhythm Pharmaceuticals employs 54 workers across the globe.

What is Rhythm Pharmaceuticals' official website?

The official website for Rhythm Pharmaceuticals is www.rhythmtx.com.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-264-4280 or via email at [email protected]

This page was last updated on 6/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.